JP2024526773A - B7‐h3抗体の医薬組成物及びその使用 - Google Patents

B7‐h3抗体の医薬組成物及びその使用 Download PDF

Info

Publication number
JP2024526773A
JP2024526773A JP2024502056A JP2024502056A JP2024526773A JP 2024526773 A JP2024526773 A JP 2024526773A JP 2024502056 A JP2024502056 A JP 2024502056A JP 2024502056 A JP2024502056 A JP 2024502056A JP 2024526773 A JP2024526773 A JP 2024526773A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cancer
enoblituzumab
composition
container
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024502056A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024526773A5 (cg-RX-API-DMAC10.html
Inventor
チョウ,ヤン
サンパスクマール,クリシュナン
バーク,スティーブン,ジェームズ
ワン,シャオヤン
Original Assignee
マクロジェニクス,インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マクロジェニクス,インコーポレーテッド filed Critical マクロジェニクス,インコーポレーテッド
Publication of JP2024526773A publication Critical patent/JP2024526773A/ja
Publication of JP2024526773A5 publication Critical patent/JP2024526773A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2024502056A 2021-07-16 2022-07-06 B7‐h3抗体の医薬組成物及びその使用 Pending JP2024526773A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163222750P 2021-07-16 2021-07-16
US63/222,750 2021-07-16
PCT/US2022/073462 WO2023288173A1 (en) 2021-07-16 2022-07-06 Pharmaceutical compositions of a b7-h3 antibody and use of the same

Publications (2)

Publication Number Publication Date
JP2024526773A true JP2024526773A (ja) 2024-07-19
JP2024526773A5 JP2024526773A5 (cg-RX-API-DMAC10.html) 2025-07-10

Family

ID=84920541

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024502056A Pending JP2024526773A (ja) 2021-07-16 2022-07-06 B7‐h3抗体の医薬組成物及びその使用

Country Status (11)

Country Link
US (1) US20240336687A1 (cg-RX-API-DMAC10.html)
EP (1) EP4370155A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024526773A (cg-RX-API-DMAC10.html)
KR (1) KR20240038005A (cg-RX-API-DMAC10.html)
CN (1) CN117715657A (cg-RX-API-DMAC10.html)
AU (1) AU2022310668A1 (cg-RX-API-DMAC10.html)
CA (1) CA3224118A1 (cg-RX-API-DMAC10.html)
IL (1) IL310187A (cg-RX-API-DMAC10.html)
MX (1) MX2024000690A (cg-RX-API-DMAC10.html)
TW (1) TW202310874A (cg-RX-API-DMAC10.html)
WO (1) WO2023288173A1 (cg-RX-API-DMAC10.html)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013531679A (ja) * 2010-07-02 2013-08-08 メディミューン,エルエルシー 抗体製剤
US20140328750A1 (en) * 2010-03-04 2014-11-06 Macrogenics, Inc. Antibodies Reactive with B7-H3 and Uses Thereof
WO2020200099A1 (zh) * 2019-03-29 2020-10-08 江苏恒瑞医药股份有限公司 包含抗il-5抗体的药物组合物及其用途
JP2021506922A (ja) * 2017-12-22 2021-02-22 江蘇恒瑞医薬股▲ふん▼有限公司 Lag−3抗体医薬組成物およびその使用
WO2021133653A1 (en) * 2019-12-23 2021-07-01 Macrogenics, Inc. Therapy for the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230041197A1 (en) * 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
CN115103691B (zh) * 2020-03-25 2025-01-24 苏州盛迪亚生物医药有限公司 一种含抗体药物偶联物的药物组合物及其用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140328750A1 (en) * 2010-03-04 2014-11-06 Macrogenics, Inc. Antibodies Reactive with B7-H3 and Uses Thereof
JP2013531679A (ja) * 2010-07-02 2013-08-08 メディミューン,エルエルシー 抗体製剤
JP2021506922A (ja) * 2017-12-22 2021-02-22 江蘇恒瑞医薬股▲ふん▼有限公司 Lag−3抗体医薬組成物およびその使用
WO2020200099A1 (zh) * 2019-03-29 2020-10-08 江苏恒瑞医药股份有限公司 包含抗il-5抗体的药物组合物及其用途
WO2021133653A1 (en) * 2019-12-23 2021-07-01 Macrogenics, Inc. Therapy for the treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"A Phase II Trial of Neoadjuvant Enoblituzumab (MGA271) in Men with Localized Intermediate- and High-", ジョンズホプキンス大学 プロトコル VER.4.0, JPN7026003331, 17 April 2019 (2019-04-17), pages 37 - 1, ISSN: 0005915578 *

Also Published As

Publication number Publication date
EP4370155A4 (en) 2025-06-11
WO2023288173A1 (en) 2023-01-19
AU2022310668A1 (en) 2024-01-18
CA3224118A1 (en) 2023-01-19
MX2024000690A (es) 2024-02-07
KR20240038005A (ko) 2024-03-22
US20240336687A1 (en) 2024-10-10
CN117715657A (zh) 2024-03-15
IL310187A (en) 2024-03-01
EP4370155A1 (en) 2024-05-22
TW202310874A (zh) 2023-03-16

Similar Documents

Publication Publication Date Title
JP6113756B2 (ja) 抗ang2抗体を含有する安定化製剤
US20150239970A1 (en) Stable, Low Viscosity Antibody Formulation
US20210252146A1 (en) Stable antibody formulation
TWI609696B (zh) 包含抗-dll4抗體的穩定化調配物
SG11202108627SA (en) Therapeutic antibody formulation
US12364756B2 (en) Pharmaceutical compositions of a PD-1 antibody and use of the same
KR20240038005A (ko) B7-h3 항체의 약학적 조성물 및 그것의 용도
KR20240100493A (ko) 항-cd22 항체의 수성 제제 및 이의 용도
US11459399B2 (en) Pharmaceutical compositions of a HER2/neu antibody and use of the same
US20230053747A1 (en) Pharmaceutical Compositions of a HER2/neu Antibody and Use of the Same
CN116916952A (zh) HER2/neu抗体的药物组合物及其用途
HK40112469A (en) Pharmaceutical compositions of a pd-1 antibody and use of the same
HK40102521A (en) Pharmaceutical compositions of a her2/neu antibody and use of the same
EA050933B1 (ru) Фармацевтические композиции антитела к pd-1 и применение указанной композиции
TWI771335B (zh) 穩定藥學調配物
TW202128220A (zh) 穩定液體組合物、其製備方法及含有其之調配物
WO2024190892A1 (ja) 抗体製剤
KR20230026407A (ko) 액티빈 a 항체 제형 및 이의 사용 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250702

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250702

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260724